| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.8M | — | +215.2% |
| SG&A Expense | $1.4M | — | +39.4% |
| Operating Income | -$4.2M | — | -122.6% |
| Net Income | -$4.0M | — | -126.3% |
| EPS (Basic) | -$0.34 | — | +17.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $17.0M | -19.0% | +28.3% |
| Current Assets | $17.4M | -19.0% | +29.5% |
| Total Assets | $17.4M | -19.0% | +29.6% |
| Total Liabilities | $950K | -29.1% | -25.2% |
| Stockholders' Equity | $16.5M | -18.3% | +35.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.0M | — | -214.0% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $3K | — | +250.0% |
| Financing Cash Flow | $0 | — | -100.0% |
| Free Cash Flow | -$4.0M | — | -213.5% |